Brief: GRI Bio Reports 6-Week Interim Lung Function Data In Ongoing Phase 2A Study In Idiopathic Pulmonary Fibrosis
11/09/2025 15:11
Sept 11 (Reuters) - GRI Bio Inc GRI.O: GRI BIO REPORTS 6-WEEK INTERIM LUNG FUNCTION DATA IN ONGOING PHASE 2A STUDY IN IDIOPATHIC PULMONARY FIBROSIS (“IPF”) GRI BIO INC - GRI-0621 SHOWS NO WORSENING OF FVC AT 6 WEEKS GRI BIO INC - PHASE 2A STUDY FULLY ENROLLED; TOPLINE DATA EXPECTED Q3 2025 GRI BIO INC - NO SAFETY CONCERNS OBSERVED BY IDMC IN GRI-0621 STUDY Source text: ID:nGNX8kbn7x Further company coverage: GRI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on GRI Bio
See all newsGRI Bio Inc reports results for the quarter ended June 30 - Earnings Summary
GRI Bio Inc expected to post a loss of $1.19 a share - Earnings Preview
Brief: Gri Bio Secures FDA Orphan Drug Designation For Gri-0621 (Tazarotene) In Idiopathic Pulmonary Fibrosis
GRI Bio Q1 net loss narrows on lower R&D expenses
GRI Bio raises $14.5 mln to fund operations into Q1 2027